Publications

Butler B, Velazquez AI, Trejo E, Huppert LA, Hsu G, Babik JM, Santhosh L. How do Internal Medicine Residents from Different Backgrounds Make Subspecialty Career Choices? A Qualitative Analysis. Journal of general internal medicine. 2025. PMID: 41269511

Leite LF, da Conceição LD, Saldanha EF, Menezes S, de Melo AC, Borea R, Corassa M, Manana AV, Cardona AF, Arrieta O, Rios-Garcia E, Corrales L, Rolfo C, Cordeiro de Lima VC. Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022. Cancer Research Communications. 2025. PMID: 41259656

Mulima G, Mody GN, Kaimila B, Salima A, Williams B, Paciorek A, Zhang L, Charles A, Westmoreland KD, Van Loon K, Buckle GC. Treatment Outcomes of Esophageal Cancer in Malawi: An Analysis of Overall Survival and Patient-Reported Outcomes. JCO global oncology. 2025. PMID: 41232057

Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O. Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. The oncologist. 2025. PMID: 41056445

Panian J, Henderson NC, Herchenhorn D, Barata PC, Bilen MA, Graham L, Heath E, Hwang C, Supernois A, Kilari D, Thapa B, Koshkin VS, Jindal T, Nauseef JT, Sokolova A, Amery T, Zakharia Y, Schweizer MT, Raychaudhuri R, Reichert ZR, Dorff T, Armstrong AJ, Wang J, Alva A, McKay RR. Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617. The oncologist. 2025. PMID: 41124032

Li H, Melnyk JE, Fu BXH, Shrestha R, Zhang M, Sjöström M, Feng S, Anderson JA, Han W, Chesner LN, Shin HJ, Farsh T, Suarez HJ, Nath S, Chou J, Das R, Egusa EA, Calvert M, Kishishita A, Barpanda A, Zhu J, Maheshwari A, Chen WS, Alshalalfa M, Winters A, Hua JT, Liu T, Davicioni E, Wiita AP, Stohr BA, Siddiqui J, Huang B, Small EJ, Shokat KM, Nelson PS, Quigley DA, Wasmuth EV, Gilbert LA, Feng FY. Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer. Nature genetics. 2025. PMID: 41193657

Greenland NY, Cowan JE, Ding CC, Sirohi D, Cooperberg MR, Carroll PR, Simko JP, Stohr BA, Zhang L, Chan E. Correlation of unfavourable and favourable histology at radical prostatectomy with Decipher scores and freedom from biochemical recurrence. Histopathology. 2025. PMID: 41171098

Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. Urologic oncology. 2025. PMID: 41152111

Julia Ye MD, PhD, Nadine Goldhammer PhD, Poonam Vohra MD, Shruti Warhadpande MS, George C. de Castro MD, Cristian K. Maldonado Rodas BS, Mark M. Moasser MD, Kirithiga Ramalingam MD, MAS, Shoko E. Abe MD, Michael Alvarado MD, Cheryl Ewing MD, Karen M. Goodwin DO, FACS, Rita A. Mukhtar MD, Jasmine M. Wong MD, Laura J. Esserman MD, MBA, Ronald Balassanian MD, Jennifer M. Rosenbluth MD, PhD. FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ Cancer cytopathology. 2025. PMID:

DeBoer RJ, Uwamahoro P, Ndoli DA, Rugengamanzi E, Mulindabigwi A, Bigirimana JB, Musafiri T, Slater SE, Van Loon K, Sudore RL, Anderson WG, Sanders JJ, Cubaka VK. Adaptation of a serious illness communication training intervention for the Rwandan context. Journal of pain and symptom management. 2025. PMID: 41135916

Johanna Balas, Lauren Bowling, Nonna Shakhnazaryan, Rahul Raj Aggarwal, Hala Borno, Julian C. Hong, Franklin W. Huang, Barry Tong, Daniel H. Kwon. Evaluating an artificial intelligence (AI) communication platform for racial biases in information quality about prostate cancer (PCa) germline testing. JCO oncology practice. 2025. PMID:

Schram AM, Naqash AR, Haura EB, Riess JW, Ulahannan SV, Ou SI, Munster PN, Cheng ML, Gustafson WC, Bitman B, Friedman R, Penn R, Kar S, Seshadri V, Wang Z, Tao L, Yang YC, Singh M, Burris HA, Meyerowitz JG. The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 41056387

Christopher N. Johns, Hala T. Borno, Samuel L. Washington, Wesley Robinson, Miriam Perales, Rahul R. Aggarwal, Rohit Bose, Jonathan Chou, Ivan de Kouchkovsky, Arpita Desai, Kelly N. Fitzgerald, Terence W. Friedlander, Vadim S. Koshkin, Elizabeth Pan, Eric J. Small, Noah S. Younger, Xiaolin Zhu, Franklin W. Huang, Daniel H. Kwon. Development of a Culturally Tailored Educational Tool to Increase Somatic Testing Participation Among Black Men With Metastatic Prostate Cancer. JCO Oncology Advances. 2025. PMID:

Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. Cancer medicine. 2025. PMID: 41031719

Rahmani R, Kang H, Chan JW. A Patient With Prior Skin Cancers and New Diagnosis of Bell Palsy. JAMA oncology. 2025. PMID: 40773185

Uwamahoro P, Girukubonye I, Bigirimana JB, Shyirambere C, Van Loon K, Sudore RL, Sanders JJ, Cubaka VK, DeBoer RJ. Setting the stage for communication skills training in Rwandan cancer care: a qualitative study of local priorities and key contextual factors. BMC palliative care. 2025. PMID: 41029628

Smabers LP, Wensink GE, Verissimo CS, Doorn M, Yang T, Voskuilen T, Huismans MA, Valkenburg-van Iersel L, Cirkel GA, Gootjes EC, Verheul HMW, Jeurissen FJ, Bol GM, Nienhuis HH, Braat MNGJA, Cuppen E, Vries RGJ, van der Baan FH, Elias SG, Kranenburg O, Koopman M, Boj SF, Roodhart JML. Patient-derived organoids predict treatment response in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40982295

Chari A, van de Donk NWCJ, Dholaria B, Weisel KC, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosiñol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi KK, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit D, Wäsch R. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025. PMID: 40983036

Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40689871

Chari A, Shenoy S, Kruyswijk S, Hilder B, O'Rourke L, van de Donk NWCJ. Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary. Future oncology (London, England). 2025. PMID: 40951933